Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biondvax Pharma ADR (NQ: BVXV ) N/A UNCHANGED Last Price Updated: 3:59 PM EDT, Sep 6, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 1.250 (3) Ask (Size) 1.380 (2) Prev. Close 1.360 Today's Range N/A - N/A 52wk Range 1.250 - 1.870 Shares Outstanding 461,285,824 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News BC Study Uncovers Cause of Four Major Pediatric Allergies September 07, 2023 Via Investor Brand Network BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd. September 06, 2023 Via Investor Brand Network Performance More News Read More BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics September 06, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs September 01, 2023 Via Investor Brand Network Exposures Product Safety Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes August 31, 2023 Via Investor Brand Network England Sees Soaring Numbers of Hospitalizations for Severe Allergies August 28, 2023 Via Investor Brand Network BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17 August 25, 2023 Via Investor Brand Network How Allergy Sufferers Can Benefit from Immunotherapy August 22, 2023 Via Investor Brand Network Analyzing Link Between Hormonal Contraceptives, Autoimmunity August 18, 2023 Via Investor Brand Network BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment August 18, 2023 Via Investor Brand Network BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update August 16, 2023 Via Investor Brand Network Stem Cell Transplants Followed by Immunotherapy Show Efficacy Against Pediatric Nerve Tumors August 15, 2023 Via Investor Brand Network BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics August 14, 2023 Via Investor Brand Network Exposures COVID-19 BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update August 11, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax Reports Second Quarter Financial Results and Provides Business Update August 11, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire How Immunotherapy Outcomes Can Be Affected by Diet, Gut Microbiota August 09, 2023 Via Investor Brand Network Study Finds Link Between Food Allergies in Infants, Childhood Asthma Onset August 03, 2023 Via Investor Brand Network BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance August 02, 2023 Via Investor Brand Network Exposures COVID-19 Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules August 01, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets July 28, 2023 Via Investor Brand Network Review Shows AI Could Be Pivotal in Infectious Disease Prevention July 28, 2023 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence COVID-19 M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) July 26, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) CDMO Services Designed to Meet Needs of Pharmaceutical, Biotechnology Companies of All Sizes July 24, 2023 Via Investor Brand Network Exposures COVID-19 Psoriasis Could Be Behind Frequent Fatigue July 24, 2023 Via Investor Brand Network BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast July 19, 2023 Via Investor Brand Network Exposures COVID-19 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.